Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + Bevacizumab with Pemetrexed and Platinum in Advanced NSCLC Without Targeted Therapy
ChiCTR2400089107Phase 4Not yet recruiting
- Sponsor
- Anhui Chest Hospital
- Start
- Sep 2024
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of sintilimab, bevacizumab, pemetrexed, carboplatin and cisplatin in non-small cell lung cancer (NSCLC), sponsored by Anhui Chest Hospital. Primary endpoints: Progression-free survival, Objective response rate and 1 more. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
sintilimabbevacizumabpemetrexedcarboplatincisplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2400089107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400089107.